• Last week, the U.S. Supreme Court issued its unanimous opinion in Association for Molecular Pathology v. Myriad Genetics, where the Court held that Myriad’s claims on isolated genes were not patent-eligible subject matter under Section 101.  Patently-O has a good round-up on the decision, as well as some thoughts from various members of

…